Alpha 2.0
Login Register
» Articles » PMID: 35758004

Clinical Progress of KRAS-targeted Therapies: What Next?

Overview
Journal Future Med Chem
Specialties Chemistry
Pharmacy
Date 2022 Jun 27
PMID 35758004
Authors
Misako Nagasaka
Asfar S Azmi
Affiliations
Soon will be listed here.
Citing Articles

Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS.

Kaczmarczyk J, Whiteley G, Blonder J Methods Mol Biol. 2024; 2823:269-289.

PMID: 39052226 DOI: 10.1007/978-1-0716-3922-1_17.

Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells.

Ye X Methods Mol Biol. 2024; 2823:27-46.

PMID: 39052212 DOI: 10.1007/978-1-0716-3922-1_3.

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.

Shu C, Liu Y Cancer Manag Res. 2022; 14:3485-3492.

PMID: 36561983 PMC: 9767706. DOI: 10.2147/CMAR.S387665.

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.

Brazel D, Arter Z, Nagasaka M Lung Cancer (Auckl). 2022; 13:75-80.

PMID: 36387582 PMC: 9662012. DOI: 10.2147/LCTT.S383662.